Although adenomas were reduced with sulindac alone and PP+sulindac in the Apcmin/+ mice, these results indicate that a combination of anti-inflammatory treatment with a Wnt pathway inhibitor provides an opportunity for reducing tumor number and burden in Apc-defective colon adenoma cells. Here, APC is linked to adenoma.